Skip to Content

Dacomitinib use while Breastfeeding

Drugs containing Dacomitinib: Vizimpro

Medically reviewed by Drugs.com. Last updated on Dec 31, 2020.

Dacomitinib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 70 hours, the manufacturer recommends that breastfeeding be discontinued during dacomitinib therapy and for at least 17 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Dacomitinib

CAS Registry Number

1110813-31-4

Drug Class

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Tyrosine Kinase Inhibitors
  • Lactation
  • Breast Feeding

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.